Travere Therapeutics Inc. stocks have been trading up by 34.27 percent following highly positive drug development and regulatory progress news.
Click Here for a Millionaire's POV on Trading TVTX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For TVTX Traders
- Full FDA approval for FILSPARI in FSGS makes it the first and only approved medicine in this kidney disease and broadens Travere Therapeutics’ reach to over 100,000 U.S. patients.
- The new FSGS label adds a first‑in‑class option for about 30,000 U.S. patients, opening a fresh revenue lane for TVTX.
- Citi reaffirmed a Buy on TVTX with a $48 target and an “upside 90‑day catalyst watch,” arguing the market was underpricing the FSGS opportunity.
- JPMorgan nudged its TVTX target down to $41 but kept an Overweight stance, signaling ongoing confidence despite small‑cap biotech recalibration.
- Shares of Travere Therapeutics recently spiked 9.5% to $33.33 in one session, showing strong momentum trading ahead of the approval.
Live Update At 12:32:44 EDT: On Tuesday, April 14, 2026 Travere Therapeutics Inc. stock [NASDAQ: TVTX] is trending up by 34.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TVTX has been trading like a biotech name digesting a major win. On the daily chart, Travere Therapeutics climbed from around $26–$28 in late March to $41.21 on 2026/04/14. That is a powerful trend move, especially with a big gap from $30.70 on 2026/04/13 to above $41 the next session as traders reacted to the FDA news on FILSPARI.
Intraday, TVTX is showing tight action between roughly $40 and $42 after the spike, with repeated tests of the low $40s holding. That tells traders dip‑buyers are active and shorts are cautious. For now, $40 is acting like a key intraday line in the sand.
More Breaking News
- OWL Stock Holds Ground As Wall Street Trims Targets
- JBLU Stock Jumps As Sale Talk Meets Turnaround Push
- RIOT Stock Tests Support As Volatility Returns To Bitcoin Miners
- HOOD Stock Rallies As Wall Street Backs Post‑Q1 Rebound Story
On the fundamentals, Travere Therapeutics printed about $490.7M in revenue over the trailing period, with revenue growing almost 65% over three years. Gross margin near 97.9% is typical for a specialty biotech, but profit margins are still negative as TVTX spends heavily on research and commercialization. Cash and short‑term investments of about $322.8M versus total debt around $322.9M show a leveraged, but not desperate, balance sheet. For traders, that mix means big upside on good news — and sharp pullbacks when sentiment turns.
Why Traders Are Watching TVTX After The FDA Win
TVTX is front and center on biotech screens because Travere Therapeutics just cleared a key regulatory hurdle. The company secured full FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This is not a small label tweak. It makes FILSPARI the first and only approved medicine for FSGS, and it extends Travere Therapeutics’ reach beyond IgA nephropathy into a combined U.S. addressable population north of 100,000 patients.
For active traders, that is a classic de‑risking event. A big binary catalyst is now in the rear‑view mirror, and TVTX suddenly has a clearer path to meaningful revenue growth. Within that larger population, the FSGS piece alone represents about 30,000 U.S. patients. That kind of first‑in‑class foothold in a rare disease space gets institutions’ attention, and it explains why TVTX has been on so many momentum watchlists.
Analysts were lining up ahead of this catalyst. Citi kept a Buy rating on Travere Therapeutics, slapped a $48 price target on TVTX, and put the name on an “upside 90‑day catalyst watch” before the approval date, arguing the market was underestimating FILSPARI’s FSGS shot. Now that the FDA has signed off, that call looks on point and can keep sentiment supportive.
JPMorgan took a more measured route, cutting its target from $44 to $41 but still calling TVTX Overweight as part of a broader small‑cap biotech reset. That tells traders the Street still sees room above recent prices, even while staying disciplined on valuation.
Add in that sharp 9.5% pop to $33.33 in an earlier session — before the full approval — and it is clear TVTX has been a magnet for speculative flows. The current action near $41, with volume‑backed dips getting bought, shows those traders are still very active.
Conclusion
TVTX now sits at the intersection of a powerful catalyst and an energetic chart. Travere Therapeutics has taken FILSPARI from a focused IgA nephropathy play to a first‑in‑class therapy for FSGS, unlocking a U.S. market that now spans more than 100,000 potential patients. For traders, that changes the story from “if” to “how fast” management can execute on this expanded label.
Analyst support adds fuel. Citi’s $48 target and prior “upside 90‑day catalyst watch” on TVTX show that some on Wall Street were already leaning bullish into this FDA call. JPMorgan’s trimmed but still‑constructive $41 target underlines a key point: even cautious models see Travere Therapeutics as more upside than downside at current levels, while still flagging small‑cap biotech risk.
The price action lines up with that narrative. TVTX has ripped from the high $20s to the low $40s in a few weeks, with intraday trading now coiling around the $40 area. That is exactly the type of post‑news consolidation that short‑term traders study for secondary moves — either a breakout continuation or a hard snap‑back for disciplined shorts. This is where pure trading discipline matters most. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” That kind of momentum‑first mindset can help traders frame TVTX as a real‑time pattern and price‑action setup, rather than a guessing game about distant outcomes.
As Tim Sykes loves to say, “The pattern tells the story — your job is to read it without getting emotional.” With Travere Therapeutics now a proven catalyst runner, traders who stay patient, respect risk, and let the TVTX chart confirm their thesis will be the ones still standing after the noise fades.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.